Amivantamab and Recombinant Human Hyaluronidase Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Also known as: Amivantamab + Recombinant Human Hyaluronidase, Amivantamab Plus Recombinant Human Hyaluronidase, Amivantamab and Hyaluronidase, Amivantamab and Hyaluronidase-lpuj, Amivantamab with Recombinant Human Hyaluronidase +4 more

Pipeline

Phase 2: 1

Top Sponsors

National Cancer Institute (NCI)1

Indications

Locally Recurrent Skin Squamous Cell Carcinoma1
Metastatic Skin Squamous Cell Carcinoma1
Cancer1

Birmingham, Alabama1 trial

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

University of Alabama at Birmingham Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.